You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Médicaments

La bibliothèque de médicaments donne accès à des renseignements sur plus de 100 médicaments anticancéreux commercialisés au Canada.

Trouvez plus d’information sur la sécurité  dans le document patient supplémentaire Comment prendre vos médicaments oraux contre le cancer de manière sécuritaire.

Displaying Drugs List

16 Items
Other Name(s): Xeloda®
Funding:
ODB - General Benefit
  • capecitabine
Dec 2019
Nov 2019
Updated
Feb 2020
Other Name(s): Procytox®
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
Jun 2019
Jun 2019
Other Name(s): Adriamycin®
Sep 2019
Other Name(s): Vepesid®
Funding:
ODB - General Benefit
  • etoposide - oral capsules
Sep 2019
Other Name(s): Adrucil® (multiple brands available); Efudex® Cream (Valeant)
May 2018
Other Name(s): Gemzar® (multiple brands available)
Funding:
New Drug Funding Program
  • Gemcitabine - Carcinoma of Bladder or Urothelium
  • Gemcitabine - Non-Small Cell Lung Cancer (NSCLC)
  • Gemcitabine - Advanced Pancreatic Cancer
Feb 2018
Other Name(s): Lenvima (Eisai)
Funding:
Exceptional Access Program
  • For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria
Oct 2017
Other Name(s): Lysodren®
Jun 2019
Other Name(s): Sandostatin® (multiple brands available); Sandostatin® LAR™ (Novartis)
Funding:
ODB - General Benefit
  • octreotide
Aug 2016